natgillin/translations-raw huggingface dataset:
Method according to claim 4 characterized by the fact that said storage folder (C) stores multimedia contents (R1,..., RN) associated to different types (T1,..., TN). 
Metoda prema patentnom zahtjevu 4, naznačena time da se u navedenoj mapi za pohranu (C) spremaju multimedijalni sadržaji (RI,..., RN) povezani s raznim vrstama (T1,..., TN).
In the second embodiment of the invention, represented in table 11, resistant maltodextrin is present in an amount up to 20 weight %, preferably 10 to 15 weight %. 
U drugoj varijanti, prikazanoj u Tablici 11, rezistentni je maltodekstrin prisutan u količini do 20 težinskih %, pri čemu se prednost daje količini od 10 do 15 težinskih %.
In turn, the anhydrous form of Meldonium is unstable and extremely hygroscopic. 
Sa svoje strane, bezvodni oblik meldonija je nepostojan i ekstremno je higroskopan.
The use of a pyrethroid or pyrethrin and an organophosphate or carbamate for the preparation of topical sea lice treatment agent compositions for use in a method of treatment of farmed fish to combat infestation by multicellular ectoparasites with exoskeletons, which method comprises topically exposing farmed fish to a first and a second sea lice treatment agent sequentially, said first sea lice treatment agent being a carbamate or organophosphate and said second sea lice treatment agent being a pyrethroid or pyrethrin, wherein exposure to the first sea lice treatment agent is effected 10 minutes to 12 hours before exposure to the second sea lice treatment agent. 
Uporaba piretroida ili piretrina i organofosfata ili karbamata za pripremu topikalnih smjesa sredstava protiv morskih uši za uporabu u postupku tretmana uzgajanih riba radi borbe protiv infestacije višestaničnim ektoparazitima sa egzoskeletom, taj postupak obuhvaća uzastopni topikalni tretman uzgajanih riba s prvim i drugim sredstvom protiv morskih uši, to prvo sredstvo protiv morskih uši je karbamat ili organofosfat i drugo sredstvo protiv morskih uši je piretroid ili piretrin, pri čemu izloženost prvom sredstvu protiv morskih uši traje 10 minuta do 12 sati prije izlaganja drugom sredstvu protiv morskih uši.
The antibody for use or the composition for use of claim 13, wherein the second agent is a non-steroidal anti-inflammatory drug such as ibuprofen, naproxen, sulindac, diclofenac, piroxicam, ketoprofen, diflunisal, nabumetone, etodolac, and oxaprozin, indomethacin; an anti-malarial drug such as hydroxychloroquine; a corticosteroid hormone, such as prednisone, hydrocortisone, methylprednisolone, and dexamethasone; methotrexate; an immunosuppressive agent, such as azathioprine and cyclophosphamide; or a biologic agent that, e.g., targets T cells, such as Alefacept and Efalizumab, or targets TNFa, such as, etanercept, infliximab, and adalimumab. 
Protutijelo za uporabu ili pripravak za uporabu prema zahtjevu 13, naznačeno time da drugo sredstvo je nesteroidni protuupalni lijek kao što su ibuprofen, naproksen, sulindak, diklofenak, piroksikam, ketoprofen, diflunisal, nabumeton, etodolak, i oksaprozin, indometacin; lijek protiv malarije kao što je hidroksiklorokin; kortikosteroidni hormon, kao što su prednizon, hidrokortizon, metilprednizolon, te deksametazon; metotreksat; imunosupresivno sredstvo, kao što je azatioprin i ciklofosfamid; ili biološko sredstvo koja, npr., cilja T stanice, kao što je Alefacept i Efalizumab, ili cilja TNFa, kao što je, etanercept, infliksimab, te adalimumab.
Suitable irreversible acyldonors are, e.g., acyldonors such as vinyl-esters, 2-propenyl-esters or 2,2,2-trihalid-ethyl-esters. 
Postupak prema zahtjevu 33, gdje se vodik malonat spoja I priprema u alkoholnom otapalu, npr. 2-propanolu.
(iii)isolating by crystallization the compound of formula (XXI) as its HCl addition salt; 
izolacije putem kristalizacije spojaformule (XXI) kao njegove HCl adicijske soli;
Thus the compound of the invention (or the salt thereof) can be used in combination with an anti-diabetic agent including but not limited to metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, or insulin. 
(a) sredstvo za liječenje dijabetesa je metformin, sulfonilurea, glinid, DPP-IV-inhibitor, glitazon, inzulin ili analog inzulina;
The system according to claim 6, configured to generate a warning message or signal after an absolute value of the displacement exceeds a predetermined alarm threshold. 
Sustav prema jednom od patentnih zahtjeva od 7 do 10, konfiguriran za generiranje poruke upozorenja ili signala ako pomak, osobito apsolutna vrijednost pomaka, prelazi predodređenu razinu aktiviranja alarma.
The process according to claim 4, wherein the polymer is a polymethacrylate having a methyl methacrylate content of at least 80% by weight. 
Postupak prema zahtjevu 4, naznačen time što je polimer polimetakrilat koji ima sadržaj metilmetakrilata od najmanje 80 masenih %.
The conjugate of claim 4, wherein the moiety further comprises a linker comprising a polyethylene glycol. 
Konjugat iz patentnog zahtjeva 4, gdje dio od značaja sadrži ugljikohidrat.
A process according to claim 1 or 2, wherein the refrigerant composition comprises a) about 30 wt% difluoromethane (HFC-32), b) about 30 wt% pentafluoroethane (HFC-125), and c) about 40 wt% tetrafluoroethane (HFC-134a). 
Postupak prema zahtjevu 1 ili 2, naznačen time da rashladna tvar sadrži a) oko 30 tež.% difluorometana (HFC-32), b) oko 30 tež.% pentafluoroetana (HFC-125), 1 c) oko 40 tež.% tetrafluoroetana (HFC-134a).
The integrated circuit according to claim 9 wherein the pair of DVRBs assigned with the single resource block number are mapped to PRBs that are different in a time domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 13, naznačen time da su DVRB-i s ne-uzastopnim DVRB brojevima mapirani na dva od PRB-a koji su susjedni u frekvencijskoj domeni.
wherein the method comprises a step b) comprising converting at least some of said maltose to glucose; 
pretvaranje najmanje dijela navedene maltoze u glukozu; i
The present invention also relates to a slab in accordance with the technical teachings of the relative independent claim. 
Predmetni izum se dakle odnosi na ploču koja je u skladu s tehničkim saznanjima iz odgovarajućeg neovisnog patentnog zahtjeva.
A kit suitable for use in a method of any one of claims 1 to 6, said kit comprising full-length FliD or a fragment thereof and at least one further constituent, wherein the fragment is a fragment the amino acid sequence of which is shorter than the amino acid sequence of full-length FliD, whereby the fragment is still active as a virulence factor, and wherein the at least one further constituent is selected from the group consisting of a buffer, a solid phase and an instruction leaflet. 
Komplet pogodan za uporabu u postupku sukladno bilo kojem od patentnih zahtjeva 1 do 6, naznačena time, da navedeni komplet sadrži FLiD pune duljine ili njegov fragment 1 barem jedan daljnji sastojak, pri čemu je fragment fragment čija je aminokiselinska sekvenca kraća od aminokiselinske sekvenca FliD pune duljine, pri čemu je fragment još uvijek aktivan kao faktor virulencije, 1 pri čemu je najmanje jedan daljnji sastojak odabran iz skupine koja se sastoji od pufera, čvrste faze i uputa za uporabu.
The dredge tooth in accordance with anyone of claims 1-7, characterized in that the sidewalls (29, 31) generally converge toward the trailing side (27) in the digging profiles across substantially the entire length of the mounting section (23). 
Potrošni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se uz otvor (101) nalazi obilježavač (152) koji daje vidljivi znak operatoru kada je brava (16) dovoljno pritegnuta.
The method of claim 1, wherein tipifarnib is administered at a dose of 1-1000 mg/kg body weight. The method of claim 1, wherein tipifarnib is administered twice a day. The method of claim 1, wherein tipifarnib is administered at a dose of 600 mg twice a day. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarnib primijenjen u dozi od 1-1000 mg/kg tjelesne mase ili pri čemu je tipifarnib primijenjen u dozi od 600 mg dva puta dnevno ili u dozi od 900 mg dva puta dnevno.
A host cell comprising the nucleic acid or the expression vector according to claim 4, wherein said host cell is not a human embryonic stem cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5.
The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 13, naznačen time da je gustoća formulacije matrice sa produljenim otpuštanjem jednaka ili manja od oko 1.20 g/cm?, poželjno jednaka ili manja od oko 1.19 g/em'. Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 *C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37?
The polyvalent antibody according to claims 1 to 8, wherein the constant heavy chain is a Y chain. The polyvalent antibody according to claims 1 to 10, wherein the constant light chain is selected from one of the following classes: k and λ. The polyvalent antibody according to claims 1 to 11, wherein the amino acid sequence of the first polypeptide attached to two or more variable domains is selected from one of the following sequences: SEQ ID NO: 2 and SEQ ID NO: 6, and the amino acid sequence of the second polypeptide attached to two or more variable domains is selected from one of the following sequences: SEQ ID NO: 4 and SEQ ID NO: 8. 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 i IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLhB-B13-poveznica-VLhBD4-8-CL-C i dva teška lanca sa strukturom N-VHhB-813-poveznica-VHhBD4-8-CH1-CH2-CH3-C, pri čemu VLhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLh8D4-3 sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VHhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHh8D4-8 sadrži sekvencu aminokiseline SEQ ID NO: 5, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
The back opening of the box-shaped collar (2) has internal tubular threaded elements (2e) at the four corners, used to engage the fixing screws (8) of the component-holder plate (3). 
Stražnji otvor okvira koji ima oblik kutije (2) ima u četiri unutarnja kuta cijevne elemente (2€) koji imaju navoj i koji služe za zahvaćanje vijaka (8) za učvršćenje ploče za nošenje komponenti (3).
The method of claim 7, wherein the composition is in the form of a tablet, capsule, powder, pellet, suspension, emulsion, cream, gel, ointment, lotion, or paste. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedeni pripravak u obliku kreme, gela, suspenzije, masti, paste, disperzije ili emulzije.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fenpropimorph. 
CH naznačen time da je R; difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj fludioksonil.
A pharmaceutical formulation according to any one of claims 1 to 7 for use in the treatment of rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma. 
Farmaceutska formulacija u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što je namijenjena upotrebi u liječenju reumatoidnog artritisa, psorijaze, ankilozantnog spondilitisa, psorijatičnog artritisa ili multiplog mijeloma.
iii) filtering off the solid and drying the same for 4 hours under vacuum at room temperature. 
filtriranje od krutina i sušenje u vremenu od 4 sata pod vakuumom na sobnoj temperaturi.
reacting the compound according to formula (4), or salt thereof, with a biphenylic compound to obtain a compound according to formula (5), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group and 
gdje RI je vodikova ili dušikova zaštitna skupina; i c) redukcija spoja prema formuli (5) ili njegove soli, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
For the TGEC it is preferred to use an aqueous solution or suspension comprising at least one compound selected from the group consisting of hydrazine nitrate, 1,1-di C2-6 alkyl hydrazine nitrates and 1,2-di C2-6 alkyl hydrazine nitrates, such as 1,1-dimethyl hydrazine nitrate or 1,2-dimethyl hydrazine nitrate, guanidine nitrate, formamide nitric acid adduct, acetamide nitric acid adduct, urea nitric acid adduct and acetonitrile nitric acid adduct. 
Kemijski sustav prema patentnom zahtjevu 1, naznačen time, da je TGEC vodena otopina ili suspenzija koja sadrži baren jedan spoj odabran iz skupine koja se sastoji od hidrazin nitrata, 1,1-di C2g alkil hidrazin nitrata i 1,2- di C2g alkil hidrazin nitrata, kao što su 1,1-dimetil hidrazin nitrat ili 1,2-dimetil hidrazin nitrat, gvanidin nitrat, adicioni spoj formamid dušična kiselina, adicioni spoj acetamid dušična kiselina, adicioni spoj urea dušična kiselina i adicioni spoj acetonitril dušična kiselina.
The composition according to Claim 1, wherein the composition comprises microcystalline cellulose and starch in a weight ratio ranging from 1:1 to 15:1, preferably in a weight ratio of 10:1. 
Smjesa prema zahtjevu 1, gdje smjesa sadrži mikrokristaliničnu celulozu i škrob u težinskom omjeru u rasponu od 1:1 do 15:1, poželjno u težinskom omjeru od 10:1.
Surface modified calcium carbonate containing mineral of claim 23, wherein the surface modified calcium carbonate containing mineral has a BET specific surface area from 30 m2/g to about 90 m2/g and a median grain diameter from 10 µm to 50 µm, determined by Malvern Mastersizer. 
Površinski modificirani kalcijev karbonat koji sadrži mineral prema zahtjevu 21, naznačen time da površinski modificirani kalcijev karbonat koji sadrži mineral ima BET specifičnu dodirnu površinu od 30 m2/g do oko 90 m2/g i medijan promjera zrna od 10 µm do 50 µm, određeno s uređajem Malvern Mastersizer.
The composition of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds an IAPP epitope which comprises the amino acid sequence of CNTATCA (SEQ ID NO: 5). 
antitijelo koje specifično veže IAPP epitop, koji sadržava aminokiselinski slijed SSNNFGA prikazan u SEQ ID NO: 4, CNTATCA prikazan u SEQ ID NO: 5, ili QRLANFLVHS naveden u SEQ ID NO: 71;
The T cell of any one of claims 1 to 14, wherein the antigen is selected from the group consisting of prostate-specific membrane antigen (PSMA), Carcinoembryonic Antigen (CEA), IL13R alpha, her-2, CD19, NY-ESO-1, HIV-1 Gag, Lewis Y, Mart-1, gp100, tyrosinase, WT-1, hTERT, and mesothelin. 
'T-stanica prema bilo kojem od zahtjeva 1 do 14, naznačena time da je antigen odabran iz skupine koju čine membranski antigen specifičan za prostatu (PSMA), karcinoembrijski antigen (CEA), IL13R alfa, her-2, CD19, NY-ESO-I, HIV-I Gag, Lewis Y, Mart-1, gp100, tirozinaza, WT-1, hTERT, i mezotelin.
Apparatus for treating a pumpable material, the apparatus comprising: 
Naprava za obradu materijala koji se može crpsti, naznačena time, da ta naprava sadržava:
The solid form of item 2, having an X-ray powder diffraction pattern comprising peaks at about 8.6, 11.3, 13.1, 15.3, 17.3, 20.5, 22.7, 23.6, 26.3 and 31.4 degrees 2θ. 
Čvrsti oblik u skladu s patentnim zahtjevom 1, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu s maksimumima na otprilike 8,6, 11,3, 13,1, 15,3, 17,3, 20,5, 22.7, 23,6, 26,3 131,4 220.
Therefore, in a first embodiment, the invention provides a composition comprising a bacterial strain of the genus Blautia, for use in a method of treating or preventing visceral hypersensitivity. 
HR P20191096 T1 PATENTNI ZAHTJEVI Sastav koja obuhvaća bakterijski soj vrste Blaulia hydrogenotrophica, za upotrebu u postupku liječenja ili prevenciji visceralne hipersenzitivnosti.
The method of para 1, wherein said at least a portion of said CRISPR locus of said parent bacterial strain and at least a portion of said modified CRISPR locus of said bacteriophage resistant variant strain are compared by sequencing at least a portion of said CRISPR locus and at least a portion of said modified CRISPR locus. 
Postupak prema zahtjevu 1, naznačen time da se navedeni barem dio navedenog CRISPR lokusa navedenog matičnog bakterijskog soja i barem dio navedenog modificiranog CRISPR lokusa navedenih varijanti sojeva rezistentnih na bakteriofage uspoređuju sekvenciranjem barem dijela navedenog CRISPR lokusa i barem dijela navedenog modificiranog CRISPR lokusa.
Composition according to claim 14, wherein said other drug is chosen in the group consisting of Lactulose, lactitol, neomycin, metronidazole, rifaximin, and a combination of L-ornithine and L-aspartate (LOLA). 
Pripravak za uporabu u skladu sa patentnim zahtjevom 17, naznačen time što je navedeni drugi lijek odabran iz skupine koja sadrži Laktulozu, laktitol, neomicin, metronidazol, rifaksimin, i kombinaciju L-ornitina i L-aspartata (LOLA).
The method of claim 1 or claim 2, further comprising: 
Metoda iz zahtjeva 1. ili zahtjeva 2. sa sljedećim elementima:
• if the pushing force (Fp) is equal to or greater than the activation level (Fon), driving the power unit such that the average level of the pushing force (Fp) will be constant and equal to the activation level (Fon) regardless of external aspects like load, quality and tilt of surface. 
* akoje potisna sila (F,) jednaka ili veća od razine aktivacije (F,,), rad napajanja je takav da će prosječna razina potisne sile (F;) biti konstantna i jednaka razini aktivacije (F,,) neovisno od vanjskih utjecaja kao što su opterećenje, kvaliteta i nagib površine.
A compound as defined in any one of claims 1 to 6, or a composition as defined in claim 8, for use in the prevention and/or treatment of at least one disease or disorder selected from the group consisting of eye diseases; airway diseases; ear diseases; skin diseases; cardiovascular and vascular diseases; inflammatory diseases; neurological disorders; proliferative diseases; bone diseases; transplant rejection; spasm; hypertension; chronic obstructive bladder disease; and allergy. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili sastav u skladu s patentnim zahtjevom 8, za uporabu u prevenciji i/ili liječenju najmanje jedne bolesti ili poremećaja odabranog 1z skupine koja se sastoji od bolesti očiju; bolesti dišnih puteva; bolesti uha; bolesti kože; kardiovaskularnih i vaskularnih bolesti; upalnih bolesti; neuroloških poremećaja; proliferativnih poremećaja; bolesti kostiju; odbacivanja transplantanata; spazma; hipertenzije; kronične opstruktive bolesti mjehura; i alergije.
The pharmaceutical composition of any of claims 1-3 wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37 °C. 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 10 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaC1 1 63 mM FCI, pri pH 1,21 na 37%.
The combination of a catheter securement device adapted to be adhesively mounted to the skin of a patient and a catheter comprising a distal tube member, said combination comprising: 
Kombinacija uređaja za osiguravanje katetera (10) prilagođen da bude ljepljivo montiran na kožu pacijenta i kateter (130) koji sadrži član distalne cijevi (133), navedena kombinacija sadrži:
A method of receiving a broadcasting signal, the method comprising: 
Postupak primanja emitiranog signala, postupak obuhvaća:
VLP according to at least one of the above claims, characterized In that drug delivery system crosses the physiologically intact blood-brain barrier. 
VLP za uporabu u skladu s najmanje jednim od gore navedenih zahtjeva, dok VLP koji sadrži lijek prolazi fiziološki intaktnu barijeru krvi-mozak.
In one embodiment, the population of progeny T cells persists in the human for at least three months after administration. In another embodiment, the population of progeny T cells persist in the human for at least four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration. 
T stanica za upotrebu prema patentnom zahtjevu 10, naznačena time što primijenjena genetički konstruirana T stanica proizvodi populaciju potomstva T stanica koja perzistira u čovjeku najmanje tri mjeseca, četiri mjeseca, pet mjeseci, šest mjeseci, sedam mjeseci, osam mjeseci, devet mjeseci, deset mjeseci, jedanaest mjeseci, dvanaest mjeseci, dvije godine, ili tri godine nakon primjene.
The multi-layered biodegradable sheet of claim 1, wherein Layer 1 consists of 33.3% w/w PLA, 33.3% w/w PBS and 33.3% w/w PBAT; 
Višeslojna biorazgradiva folija prema zahtjevu 1, naznačena time da se sloj 1 sastoji iz 33,3% tež./tež PLA, 33,3% tež./tež.
n is between 0 and 4. The process of claim 3, wherein P is selected from the group consisting of THP or SiR1R2R3, wherein R1, R2 and R3 are independently selected from the group consisting of H, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, alkylaryl, heterocyclic, and heteroaryl. 
HR P20100218 T1 gdje R, se bira iz skupine koju čine OR> i NR:R., gdje svakog od R2, Ra i Ra se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine, gdje:
The process according to claim 1, wherein the amount of the anhydrous acid used in the ring-closure reaction is 3-15 fold as compared to the amount of 3,4-dimethoxy-phenylacetic acid of formula (III), preferably 7 fold. 
Postupak prema zahtjevu 1, pri čemu je količina bezvodne kiseline korištene u reakciji zatvaranja prstena 3-15 struka u usporedbi s količinom 3,4-dimetoksi-feniloctene kiseline formule (III), poželjno 7 -struka.
The method of paragraph 22, wherein the infectious disease caused by human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), human cytomegalovirus (HCMV), hepatitis C, papillomavirus, Plasmodium, Kaposi's sarcoma associated herpesvirus, Varicella zoster virus, Ebola virus, Mycobacterium tuberculosis, Chikungunya virus, dengue virus, monkeypox virus, herpes simplex 1, herpes simplex 2, Epstein-Barr virus (EBV), poliovirus, influenza virus, or Clostridium tetani. 
Rekombinantni vektor RhCMY ili HCMY ili pripravak u skladu s patentnim zahtjevom 13, naznačen time što zaraznu bolest uzrokuje virus humane imunodeficijencije (HIV), virus majmunske imunodeficijencije (SIV), ljudski citomegalovirus (HCMV), hepatitis C, papilomavirus, plazmodij, herpesvirus povezan s Kaposijevim sarkomom, virus varicela-zoster, virus ebole, Mycobacterium tuberculosis, virus Chikungunya, virus denge, virus majmunskih boginja, herpes simpleks 1, herpes simpleks 2, Epstein-Barrov virus (EBV), poliovirus, virus influence ili Clostridium tetani.
The container 3 is provided with a dispensing opening 8 that is closed off by a spring-loaded valve 9. 
Spremnik 3 sadrži otvor za raspršivanje 8 koji se zatvara pomoću ventila na oprugu 9.